Bellevue Life Sciences Acquisition Corp. (Nasdaq: BLAC) has signed a non-binding letter of intent (LOI) to combine with global healthcare holding company OSR Holdings, Ltd.
Seoul, South Korea-based OSR leverages its international network of partners in the US, Europe, and South Korea to develop and license its pipeline of innovative biomedical therapies based on proprietary platform technologies, with the ultimate goal of addressing unmet medical needs.
Although Bellevue did not provide much information on the potential transaction, it expects to finalize the definitive agreement within the coming weeks and will announce additional details at that time. With a November 14 completion deadline, the parties intend to complete the business combination in the fourth quarter of 2023.
Upon completion of the business combination, the surviving company will be renamed OSR Biosciences, Inc.
OSR Holdings currently wholly owns three operating subsidiaries in Switzerland and South Korea, two of which are focused on developing therapeutic drugs in the areas of oncology and osteoarthritis, and the third is a distributor of medical devices for the treatment of neurovascular and other diseases.
Additionally, OSR Holdings signed a separate LOI on July 7 to acquire Landmark BioVentures AG, a Swiss company that operates through four different biotech ventures in France with therapeutic focuses on oncology and immunology.
Bellevue Life Sciences priced its $60 million IPO earlier this year in February and initially set out to acquire a target business in the healthcare industry, specifically in the biotechnology sector developing the next generation of biologics. The SPAC is led by CEO Kuk Hyuon Hwang, CFO David J. Yoo, and Nominee for Chairman of the Board Steven Reed.
At the SPAC of Dawn Lately de-SPACs have been announcing corporate moves of a kind frequently in trios as was the case earlier this week when WeBull (NASDAQ:BULL), AST SpaceMobile (NASDAQ:ASTS) and Quantum-Si (NASDAQ:QSI) all announced major equity raises. This week, it is a trio of de-SPACs making reverse stock splits in unison, which is...
A look at Plus’ software-first approach to autonomous trucking. After years of investment and excitement, the dawn of self-driving cars and trucks is now here. The question now is which business model among autonomous driving technology companies will win out? This week, we speak with David Liu, CEO of autonomous trucking company Plus. Plus announced...
At the SPAC of Dawn One thing that SPAC investors can typically count on while their money is invested in a SPAC’s trust is that it is going to grow one way or the other between now and their next redemption opportunity, but the devil can occasionally be in the details. In 2024, it became...
Thunderstone has filed for a $50 million SPAC to put a new first-time Asia-based team in action on a generalist hunt. The new SPAC is offering investors a right to a 1/8 share in each unit with 18 months to initially complete a business combination. It is the 8th fresh S-1 filed with underwriter D....
At the SPAC of Dawn In a trading session that may find itself built around the release of Fed minutes at 2 pm ET this afternoon, a pair of SPAC targets have added their own fresh information to the mix. Enterprise AI firm Fusemachines, which has a pending combination with CSLM (OTC:CSLMF), put out a...